Genetically modified organisms

Pharming appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific Officer

Retrieved on: 
Friday, June 18, 2021
Life sciences, Articles, Branches of biology, Genetically modified organisms, Drug discovery, Genetic engineering, Molecular biology, Pharming, Chief Medical Officers, Euronext, Chief Medical Officer

LEIDEN, The Netherlands, June 18, 2021 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR)announces the appointment of Anurag Relan as Chief Medical Officer (CMO), effective immediately, and Robert Friesen as Chief Scientific Officer, effective from 1 August 2021.

Key Points: 
  • LEIDEN, The Netherlands, June 18, 2021 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR)announces the appointment of Anurag Relan as Chief Medical Officer (CMO), effective immediately, and Robert Friesen as Chief Scientific Officer, effective from 1 August 2021.
  • Anurag and Robert will be the successors of Bruno Giannetti, who was Chief Operating Officer (2006 - 2019) and Chief Medical Officer from 2019.
  • Anurag Relan is currently Vice President, Clinical Research and Medical Affairs at Pharming, having held a number of roles within the Company during the past 15 years.
  • Prior to his work at Pharming, he was in clinical practice while also teaching medical residents/students.

iBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program

Retrieved on: 
Thursday, May 6, 2021
Life sciences, Biology, Branches of biology, Biotechnology, Molecular biology, Genetically modified organisms, Vaccination, Vaccine, Virology, COVID-19 vaccine, Pharming, Immunogenicity

N proteins of many coronaviruses are highly immunogenic and are expressed abundantly during infection.

Key Points: 
  • N proteins of many coronaviruses are highly immunogenic and are expressed abundantly during infection.
  • \xe2\x80\x9cThe COVID-19 vaccine space remains highly competitive, with multiple approved vaccines in use in many countries.
  • iBio is developing proprietary products on the FastPharming Platform, which include biopharmaceuticals for the treatment of fibrotic and infectious diseases, amongst others.
  • The Company\xe2\x80\x99s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services, including Glycaneering\xe2\x84\xa2 Development Services for advanced recombinant protein design.

Pharming Group to Present at BioCapital Europe 2021

Retrieved on: 
Thursday, March 11, 2021
Branches of biology, Life sciences, Biology, Genetically modified organisms, Genetic engineering, Drug discovery, Molecular biology, Pharming, Zimmer Biomet Robotics, Medtech, Euronext

LEIDEN, The Netherlands, March 11, 2021 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announces that its Chief Executive Officer, Sijmen de Vries, will present at BioCapital Europe 2021 at 10:30 CET on 11 March 2021.

Key Points: 
  • LEIDEN, The Netherlands, March 11, 2021 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announces that its Chief Executive Officer, Sijmen de Vries, will present at BioCapital Europe 2021 at 10:30 CET on 11 March 2021.
  • BioCapital Europe, organized by LSP, is Europe's premier life sciences investment conference, offering VCs and Institutional Investors unique and timely access to around 40 exciting biotech, medtech and diagnostics companies from the Benelux and Europe.
  • To register for the event, please follow the link below via the BioCapital Europe website: https://www.biocapitaleurope.com/register/
    Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.
  • C1INH is a naturally occurring protein that down regulates the complement cascade in order to control inflammation in affected tissues.

PsyBio Therapeutics Announces Retention of Market Maker

Retrieved on: 
Thursday, March 4, 2021
Genetically modified organisms, Life sciences, Biotechnology, Genetically modified bacteria, Articles, Biology, Molecular biology, Genetic engineering

Generation does not currently own any securities of PsyBio; however, Generation and its clients may acquire a direct interest in the securities of the Company.

Key Points: 
  • Generation does not currently own any securities of PsyBio; however, Generation and its clients may acquire a direct interest in the securities of the Company.
  • PsyBio is a biotechnology company developing novel formulations of psychoactive medications using genetically modified bacteria for the treatment of mental health and other disorders.
  • The Company is also researching and developing new molecular structures that do not occur in nature which may have unique therapeutics properties.
  • Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials.

6 Things to Know About GMOs

Retrieved on: 
Thursday, February 18, 2021
Articles, Science and technology, Biology, Molecular biology, Genetic engineering, Emerging technologies, Genetically modified organisms, Genetically modified food, Pesticide, GMO conspiracy theories, Genetically modified food controversies

Although GMO foods are widely available to consumers, there is sometimes confusion around what GMOs are and how they are used in the United States' food supply.

Key Points: 
  • Although GMO foods are widely available to consumers, there is sometimes confusion around what GMOs are and how they are used in the United States' food supply.
  • GMOs can help farmers grow crops that are resistant to diseases and insects.
  • When developing GMOs, scientists run tests to make sure allergens aren't transferred from one food to another.
  • GMOs can reduce farmers' use of pesticides.Some GMO plants containplant-incorporated protectants to make them resistant to insects.

Non-GMO Project: New GMOs Created by Synbio Threaten Food Supply

Retrieved on: 
Thursday, February 4, 2021
Articles, Molecular biology, Organic food, Branches of biology, Biotechnology, Life sciences, Monsanto, Genetically modified organisms

In particular, natural and organic food brands, retailers, and consumers are in danger of finding these unregulated and unlabelled GMOs in their shopping carts.

Key Points: 
  • In particular, natural and organic food brands, retailers, and consumers are in danger of finding these unregulated and unlabelled GMOs in their shopping carts.
  • The past five years have seen an explosion in startup biotech companies using these new GMOs to create ingredients and products.
  • The threat of new GMOs in the food supply is real.
  • The article suggests that it is urgent for the natural and organic food industry to take a stand against new GMOs.

Pharming Reports on Extraordinary General Meeting of Shareholders

Retrieved on: 
Friday, December 11, 2020
Branches of biology, Life sciences, Biology, Molecular biology, Genetic engineering, Genetically modified organisms, Biological engineering, Biotechnology, Pharming, C1-inhibitor, Euronext, Extraordinary general meeting

LEIDEN, Netherlands, Dec. 11, 2020 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) announces that at its Extraordinary General Meeting of shareholders (EGM), held today, all proposals were approved.

Key Points: 
  • LEIDEN, Netherlands, Dec. 11, 2020 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) announces that at its Extraordinary General Meeting of shareholders (EGM), held today, all proposals were approved.
  • As a result, the one-tier board structure has become effective, and Barbara Yanni and Mark Pykett have been appointed as non-executive board members.
  • The flagship of our portfolio is our recombinant human C1 esterase inhibitor, or rhC1INH, franchise.
  • C1INH is a naturally occurring protein that downregulates the complement cascade in order to control swelling in affected tissues.

Existing guidance appropriate for assessment of genome editing in plants

Retrieved on: 
Tuesday, November 24, 2020
Branches of biology, Life sciences, Biology, Biotechnology, Molecular biology, Biological engineering, Emerging technologies, Genome editing, Genetically modified organisms, Mutagenesis, Genetic engineering, Genetic engineering techniques

Genome editing techniques that modify the DNA of plants do not pose more hazards than conventional breeding or techniques that introduce new DNA into a plant, an EFSA assessment concludes.

Key Points: 
  • Genome editing techniques that modify the DNA of plants do not pose more hazards than conventional breeding or techniques that introduce new DNA into a plant, an EFSA assessment concludes.
  • The scientific opinion focuses on plants produced using different genome editing techniques: site-directed nuclease-1 (SDN-1), site-directed nuclease-2 techniques (SDN-2) and oligonucleotide-directed mutagenesis (ODM).
  • Experts concluded that the existing guidance for risk assessment of genetically modified plants is applicable for the evaluation of the three new techniques.
  • Genome editing changes the DNA of animals, plants and microorganisms with high precision.

Pharming announces commitment to build a new downstream manufacturing facility for RUCONEST®

Retrieved on: 
Thursday, November 19, 2020
Life sciences, Branches of biology, Biology, Genetically modified organisms, Biological engineering, Biotechnology, Genetic engineering, Molecular biology, Pharming, C1-inhibitor, Downstream processing, Euronext

LEIDEN, The Netherlands, Nov. 19,2020 /PRNewswire/ --Pharming Group N.V. (Euronext Amsterdam: PHARM) announces it has committed to building a new facility to expand the Company's downstream processing capacity for its lead product, RUCONEST (recombinant C1 esterase inhibitor (rhC1INH)).

Key Points: 
  • LEIDEN, The Netherlands, Nov. 19,2020 /PRNewswire/ --Pharming Group N.V. (Euronext Amsterdam: PHARM) announces it has committed to building a new facility to expand the Company's downstream processing capacity for its lead product, RUCONEST (recombinant C1 esterase inhibitor (rhC1INH)).
  • The downstream processing facility will include the purification, filtration and concentration of the starting material.
  • Pivot Park is also the location of BioConnection B.V., Pharming's contracted fill and finish facility, in which Pharming holds a minority stake.
  • It is the first new building on the campus and CEO Drees hopes many more will follow.

EFSA advises on risk assessment of engineered gene drives

Retrieved on: 
Thursday, November 12, 2020
Genetic engineering, Molecular biology, Articles, Branches of biology, Life sciences, Genetically modified organisms, Emerging technologies, Gene drive, Sterilization, Genetically modified animal, European Food Safety Authority, Hazards of synthetic biology

EFSAs existing guidelines for the risk assessment of genetically modified animals are adequate for evaluating risks associated with gene drive modified insects.

Key Points: 
  • EFSAs existing guidelines for the risk assessment of genetically modified animals are adequate for evaluating risks associated with gene drive modified insects.
  • However, further guidance is needed for some areas, such as molecular characterisation, environmental risk assessment and post-market environmental monitoring, say EFSAs experts on Genetically Modified Organisms.
  • There are already proposals to use engineered gene drives to suppress or modify mosquito populations, control agricultural pests, eradicate invasive species, and rescue endangered species.
  • The European Commission asked EFSA to assess whether its existing guidelines for the risk assessment of genetically modified animals can be used for the risk assessment of gene drive modified insects.